# David E Fisher

## List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5031828/publications.pdf

Version: 2024-02-01

| | | | |
|---|---|---|---|
| 195<br>papers | 27,750<br>citations | 8208<br>78<br>h-index | 6686<br>161<br>g-index |
| 202<br>all docs | 202<br>docs citations | 202<br>times ranked | 32519<br>citing authors |

| # | ARTICLE | IF | CITATIONS |
|---|---|---|---|
| 1 | Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature, 2005, 436, 117-122. | 13.7 | 1,329 |
| 2 | Melanocyte biology and skin pigmentation. Nature, 2007, 445, 843-850. | 13.7 | 1,048 |
| 3 | MITF: master regulator of melanocyte development and melanoma oncogene. Trends in Molecular Medicine, 2006, 12, 406-414. | 3.5 | 993 |
| 4 | Mechanisms of Hair Graying: Incomplete Melanocyte Stem Cell Maintenance in the Niche. Science, 2005, 307, 720-724. | 6.0 | 984 |
| 5 | BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma. Clinical Cancer Research, 2013, 19, 1225-1231. | 3.2 | 832 |
| 6 | In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target. Nature, 2017, 547, 413-418. | 13.7 | 792 |
| 7 | Oncogenic BRAF Regulates Oxidative Metabolism via PGC1Î± and MITF. Cancer Cell, 2013, 23, 302-315. | 7.7 | 689 |
| 8 | Bcl2 Regulation by the Melanocyte Master Regulator Mitf Modulates Lineage Survival and Melanoma Cell Viability. Cell, 2002, 109, 707-718. | 13.5 | 671 |
| 9 | Selective BRAFV600E Inhibition Enhances T-Cell Recognition of Melanoma without Affecting Lymphocyte Function. Cancer Research, 2010, 70, 5213-5219. | 0.4 | 659 |
| 10 | BRAF Mutations Are Sufficient to Promote Nevi Formation and Cooperate with p53 in the Genesis of Melanoma. Current Biology, 2005, 15, 249-254. | 1.8 | 626 |
| 11 | MAP kinase links the transcription factor Microphthalmia to c-Kit signalling in melanocytes. Nature, 1998, 391, 298-301. | 13.7 | 588 |
| 12 | Central Role of p53 in the Suntan Response and Pathologic Hyperpigmentation. Cell, 2007, 128, 853-864. | 13.5 | 552 |
| 13 | Imatinib for Melanomas Harboring Mutationally Activated or Amplified <i>KIT</i> Arising on Mucosal, Acral, and Chronically Sun-Damaged Skin. Journal of Clinical Oncology, 2013, 31, 3182-3190. | 0.8 | 530 |
| 14 | Precision medicine for cancer with next-generation functional diagnostics. Nature Reviews Cancer, 2015, 15, 747-756. | 12.8 | 466 |
| 15 | Microphthalmia Gene Product as a Signal Transducer in cAMP-Induced Differentiation of Melanocytes. Journal of Cell Biology, 1998, 142, 827-835. | 2.3 | 456 |
| 16 | A Melanoma Cell State Distinction Influences Sensitivity to MAPK Pathway Inhibitors. Cancer Discovery, 2014, 4, 816-827. | 7.7 | 448 |
| 17 | Malignant melanoma: genetics and therapeutics in the genomic era. Genes and Development, 2006, 20, 2149-2182. | 2.7 | 436 |
| 18 | c-Kit triggers dual phosphorylations, which couple activation and degradation of the essential melanocyte factor Mi. Genes and Development, 2000, 14, 301-312. | 2.7 | 435 |

| # | ARTICLE | IF | CITATIONS |
|---|---|---|---|
| 19 | Major Response to Imatinib Mesylate in <i>KIT</i>-Mutated Melanoma. Journal of Clinical Oncology, 2008, 26, 2046-2051. | 0.8 | 430 |
| 20 | Melanoma. Nature Reviews Disease Primers, 2015, 1, 15003. | 18.1 | 417 |
| 21 | Melanoma: from mutations to medicine. Genes and Development, 2012, 26, 1131-1155. | 2.7 | 415 |
| 22 | A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma. Nature, 2011, 480, 99-103. | 13.7 | 413 |
| 23 | An ultraviolet-radiation-independent pathway to melanoma carcinogenesis in the red hair/fair skin background. Nature, 2012, 491, 449-453. | 13.7 | 406 |
| 24 | Intratumoral Activity of the CXCR3 Chemokine System Is Required for the Efficacy of Anti-PD-1 Therapy. Immunity, 2019, 50, 1498-1512.e5. | 6.6 | 406 |
| 25 | Critical role of CDK2 for melanoma growth linked to its melanocyte-specific transcriptional regulation by MITF. Cancer Cell, 2004, 6, 565-576. | 7.7 | 373 |
| 26 | Microphthalamia-associated transcription factor: a critical regulator of pigment cell development and survival. Oncogene, 2003, 22, 3035-3041. | 2.6 | 337 |
| 27 | The melanoma revolution: From UV carcinogenesis to a new era in therapeutics. Science, 2014, 346, 945-949. | 6.0 | 328 |
| 28 | Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion. Cancer Cell, 2015, 28, 773-784. | 7.7 | 327 |
| 29 | From genes to drugs: targeted strategies for melanoma. Nature Reviews Cancer, 2012, 12, 349-361. | 12.8 | 323 |
| 30 | Topical drug rescue strategy and skin protection based on the role of Mc1r in UV-induced tanning. Nature, 2006, 443, 340-344. | 13.7 | 302 |
| 31 | High-throughput mapping of the chromatin structure of human promoters. Nature Biotechnology, 2007, 25, 244-248. | 9.4 | 300 |
| 32 | TFE3 Fusions Activate MET Signaling by Transcriptional Up-regulation, Defining Another Class of Tumors as Candidates for Therapeutic MET Inhibition. Cancer Research, 2007, 67, 919-929. | 0.4 | 275 |
| 33 | Î²-Cateninâ€"induced melanoma growth requires the downstream target Microphthalmia-associated transcription factor. Journal of Cell Biology, 2002, 158, 1079-1087. | 2.3 | 268 |
| 34 | MLANA/MART1 and SILV/PMEL17/GP100 Are Transcriptionally Regulated by MITF in Melanocytes and Melanoma. American Journal of Pathology, 2003, 163, 333-343. | 1.9 | 266 |
| 35 | Skin Î²-Endorphin Mediates Addiction to UV Light. Cell, 2014, 157, 1527-1534. | 13.5 | 254 |
| 36 | Intronic miR-211 Assumes the Tumor Suppressive Function of Its Host Gene in Melanoma. Molecular Cell, 2010, 40, 841-849. | 4.5 | 246 |

| # | ARTICLE | IF | CITATIONS |
|---|---|---|---|
| 37 | Cloning of an Alpha-TFEB fusion in renal tumors harboring the t(6;11)(p21;q13) chromosome translocation. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 6051-6056. | 3.3 | 238 |
| 38 | Microphthalmia Transcription Factor. American Journal of Pathology, 1999, 155, 731-738. | 1.9 | 233 |
| 39 | Response to BRAF Inhibition in Melanoma Is Enhanced When Combined with Immune Checkpoint Blockade. Cancer Immunology Research, 2014, 2, 643-654. | 1.6 | 226 |
| 40 | Label-free DNA imaging in vivo with stimulated Raman scattering microscopy. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 11624-11629. | 3.3 | 225 |
| 41 | atm and p53 cooperate in apoptosis and suppression of tumorigenesis, but not in resistance to acute radiation toxicity. Nature Genetics, 1997, 16, 397-401. | 9.4 | 216 |
| 42 | Î±-Melanocyte-stimulating Hormone Signaling Regulates Expression of microphthalmia, a Gene Deficient in Waardenburg Syndrome. Journal of Biological Chemistry, 1998, 273, 33042-33047. | 1.6 | 202 |
| 43 | Pathways and therapeutic targets in melanoma. Oncotarget, 2014, 5, 1701-1752. | 0.8 | 202 |
| 44 | <i>BCL2A1</i> is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 4321-4326. | 3.3 | 200 |
| 45 | Key Roles for Transforming Growth Factor Î² in Melanocyte Stem Cell Maintenance. Cell Stem Cell, 2010, 6, 130-140. | 5.2 | 197 |
| 46 | The master role of microphthalmia-associated transcription factor in melanocyte and melanoma biology. Laboratory Investigation, 2017, 97, 649-656. | 1.7 | 197 |
| 47 | Treatment of Advanced Melanoma in 2020 and Beyond. Journal of Investigative Dermatology, 2021, 141, 23-31. | 0.3 | 193 |
| 48 | Transcriptional Regulation of the Melanoma Prognostic Marker Melastatin (TRPM1) by MITF in Melanocytes and Melanoma. Cancer Research, 2004, 64, 509-516. | 0.4 | 191 |
| 49 | Pre-bending of a promoter sequence enhances affinity for the TATA-binding factor. Nature, 1995, 373, 724-727. | 13.7 | 189 |
| 50 | Lineage-specific Signaling in Melanocytes. Journal of Biological Chemistry, 1998, 273, 17983-17986. | 1.6 | 174 |
| 51 | Oncogenic MITF dysregulation in clear cell sarcoma: Defining the MiT family of human cancers. Cancer Cell, 2006, 9, 473-484. | 7.7 | 172 |
| 52 | Hyperactivation of sympathetic nerves drives depletion of melanocyte stem cells. Nature, 2020, 577, 676-681. | 13.7 | 158 |
| 53 | Ser298 of MITF, a mutation site in Waardenburg syndrome type 2, is a phosphorylation site with functional significance. Human Molecular Genetics, 2000, 9, 125-132. | 1.4 | 150 |
| 54 | Linkage of M-CSF Signaling to Mitf, TFE3, and the Osteoclast Defect in Mitfmi/mi Mice. Molecular Cell, 2001, 8, 749-758. | 4.5 | 145 |

| # | ARTICLE | IF | CITATIONS |
|---|---|---|---|
| 55 | c-Met Expression Is Regulated by Mitf in the Melanocyte Lineage. Journal of Biological Chemistry, 2006, 281, 10365-10373. | 1.6 | 145 |
| 56 | Indoor Tanning â€" Science, Behavior, and Policy. New England Journal of Medicine, 2010, 363, 901-903. | 13.9 | 130 |
| 57 | Sumoylation of MITF and Its Related Family Members TFE3 and TFEB. Journal of Biological Chemistry, 2005, 280, 146-155. | 1.6 | 128 |
| 58 | UV Signaling Pathways within the Skin. Journal of Investigative Dermatology, 2014, 134, 2080-2085. | 0.3 | 128 |
| 59 | Imatinib Targeting of KIT-Mutant Oncoprotein in Melanoma. Clinical Cancer Research, 2008, 14, 7726-7732. | 3.2 | 126 |
| 60 | Biology and Clinical Relevance of the Micropthalmia Family of Transcription Factors in Human Cancer. Journal of Clinical Oncology, 2011, 29, 3474-3482. | 0.8 | 124 |
| 61 | Immune and molecular correlates in melanoma treated with immune checkpoint blockade. Cancer, 2017, 123, 2143-2153. | 2.0 | 119 |
| 62 | Lineage-Specific Transcriptional Regulation of DICER by MITF in Melanocytes. Cell, 2010, 141, 994-1005. | 13.5 | 113 |
| 63 | The roles of microphthalmia-associated transcription factor and pigmentation in melanoma. Archives of Biochemistry and Biophysics, 2014, 563, 28-34. | 1.4 | 109 |
| 64 | An Oncogenic Role for <i>ETV1</i> in Melanoma. Cancer Research, 2010, 70, 2075-2084. | 0.4 | 107 |
| 65 | A new era: melanoma genetics and therapeutics. Journal of Pathology, 2011, 223, 242-251. | 2.1 | 107 |
| 66 | Pharmacologic suppression of MITF expression via HDAC inhibitors in the melanocyte lineage. Pigment Cell and Melanoma Research, 2008, 21, 457-463. | 1.5 | 104 |
| 67 | How Sunlight Causes Melanoma. Current Oncology Reports, 2010, 12, 319-326. | 1.8 | 104 |
| 68 | Hypoxia-induced transcriptional repression of the melanoma-associated oncogene <i>MITF</i>. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, E924-33. | 3.3 | 101 |
| 69 | Identification of the Receptor Tyrosine Kinase c-Met and Its Ligand, Hepatocyte Growth Factor, as Therapeutic Targets in Clear Cell Sarcoma. Cancer Research, 2010, 70, 639-645. | 0.4 | 100 |
| 70 | Salt-Inducible Kinases: Physiology, Regulation by cAMP, and Therapeutic Potential. Trends in Endocrinology and Metabolism, 2018, 29, 723-735. | 3.1 | 92 |
| 71 | Isolation and Molecular Characterization of Circulating Melanoma Cells. Cell Reports, 2014, 7, 645-653. | 2.9 | 91 |
| 72 | Stem cell-released oncolytic herpes simplex virus has therapeutic efficacy in brain metastatic melanomas. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E6157-E6165. | 3.3 | 90 |

| # | ARTICLE | IF | CITATIONS |
|---|---|---|---|
| 73 | Age-resolving Osteopetrosis: A Rat Model Implicating Microphthalmia and the Related Transcription Factor TFE3. Journal of Experimental Medicine, 1998, 187, 775-785. | 4.2 | 88 |
| 74 | UV and pigmentation: molecular mechanisms and social controversies. Pigment Cell and Melanoma Research, 2008, 21, 509-516. | 1.5 | 88 |
| 75 | Identification of Aim-1 as the underwhiteMouse Mutant and Its Transcriptional Regulation by MITF. Journal of Biological Chemistry, 2002, 277, 402-406. | 1.6 | 87 |
| 76 | Genomic analysis of the Microphthalmia locus and identification of the MITF-J/Mitf-J isoform. Gene, 2005, 347, 73-82. | 1.0 | 86 |
| 77 | Regulation of MITF stability by the USP13 deubiquitinase. Nature Communications, 2011, 2, 414. | 5.8 | 86 |
| 78 | PGC-1 Coactivators Regulate MITF and the Tanning Response. Molecular Cell, 2013, 49, 145-157. | 4.5 | 84 |
| 79 | <scp>MITF</scp> and <scp>UV</scp> responses in skin: From pigmentation to addiction. Pigment Cell and Melanoma Research, 2019, 32, 224-236. | 1.5 | 84 |
| 80 | Sensorineural Deafness and Pigmentation Genes. Neuron, 2001, 30, 15-18. | 3.8 | 83 |
| 81 | A Tissue-restricted cAMP Transcriptional Response. Journal of Biological Chemistry, 2003, 278, 45224-45230. | 1.6 | 83 |
| 82 | Molecular Pathways: BRAF Induces Bioenergetic Adaptation by Attenuating Oxidative Phosphorylation. Clinical Cancer Research, 2014, 20, 2257-2263. | 3.2 | 79 |
| 83 | Epistatic connections between microphthalmiaâ€associated transcription factor and endothelin signaling in Waardenburg syndrome and other pigmentary disorders. FASEB Journal, 2008, 22, 1155-1168. | 0.2 | 78 |
| 84 | A Melanoma Molecular Disease Model. PLoS ONE, 2011, 6, e18257. | 1.1 | 77 |
| 85 | The state of melanoma: challenges and opportunities. Pigment Cell and Melanoma Research, 2016, 29, 404-416. | 1.5 | 77 |
| 86 | How does pheomelanin synthesis contribute to melanomagenesis?. BioEssays, 2013, 35, 672-676. | 1.2 | 75 |
| 87 | The Alkylating Chemotherapeutic Temozolomide Induces Metabolic Stress in <i>IDH1</i>-Mutant Cancers and Potentiates NAD+ Depletionâ€"Mediated Cytotoxicity. Cancer Research, 2017, 77, 4102-4115. | 0.4 | 74 |
| 88 | Skin pigmentation and its control: From ultraviolet radiation to stem cells. Experimental Dermatology, 2021, 30, 560-571. | 1.4 | 74 |
| 89 | Indoor ultraviolet tanning and skin cancer: health risks and opportunities. Current Opinion in Oncology, 2009, 21, 144-149. | 1.1 | 72 |
| 90 | Cell-state dynamics and therapeutic resistance in melanoma from the perspective of MITF and IFNÎ³ pathways. Nature Reviews Clinical Oncology, 2019, 16, 549-562. | 12.5 | 72 |

| # | ARTICLE | IF | CITATIONS |
|---|---|---|---|
| 91 | Control of melanocyte differentiation by a MITFâ€"PDE4D3 homeostatic circuit. Genes and Development, 2010, 24, 2276-2281. | 2.7 | 68 |
| 92 | Lighting a path to pigmentation: mechanisms of MITF induction by UV. Pigment Cell and Melanoma Research, 2010, 23, 741-745. | 1.5 | 67 |
| 93 | Prognostic Significance of Cutaneous Adverse Events Associated With Pembrolizumab Therapy. JAMA Oncology, 2015, 1, 1340. | 3.4 | 63 |
| 94 | A UV-Independent Topical Small-Molecule Approach for Melanin Production in Human Skin. Cell Reports, 2017, 19, 2177-2184. | 2.9 | 59 |
| 95 | Extensive apoptosis in ductal carcinoma in situ of the breast. , 1996, 77, 1831-1835. |  | 54 |
| 96 | Epitope spreading toward wild-type melanocyte-lineage antigens rescues suboptimal immune checkpoint blockade responses. Science Translational Medicine, 2021, 13, . | 5.8 | 54 |
| 97 | The State of Melanoma: Emergent Challenges and Opportunities. Clinical Cancer Research, 2021, 27, 2678-2697. | 3.2 | 53 |
| 98 | A phase I trial of panobinostat (<scp>LBH</scp>589) in patients with metastatic melanoma. Cancer Medicine, 2016, 5, 3041-3050. | 1.3 | 51 |
| 99 | Diffuse large cell lymphoma with discordant bone marrow histology. Clinical features and biological implications. Cancer, 1989, 64, 1879-1887. | 2.0 | 48 |
| 100 | Genome-Wide DNA Methylation Analysis in Melanoma Reveals the Importance of CpG Methylation in MITF Regulation. Journal of Investigative Dermatology, 2015, 135, 1820-1828. | 0.3 | 46 |
| 101 | Destabilization of NOXA mRNA as a common resistance mechanism to targeted therapies. Nature Communications, 2019, 10, 5157. | 5.8 | 46 |
| 102 | YY1 Regulates Melanocyte Development and Function by Cooperating with MITF. PLoS Genetics, 2012, 8, e1002688. | 1.5 | 45 |
| 103 | ZBTB7A Suppresses Melanoma Metastasis by Transcriptionally Repressing MCAM. Molecular Cancer Research, 2015, 13, 1206-1217. | 1.5 | 44 |
| 104 | Gain-of-Function Genetic Alterations of G9a Drive Oncogenesis. Cancer Discovery, 2020, 10, 980-997. | 7.7 | 44 |
| 105 | Metastatic melanoma and immunotherapy. Clinical Immunology, 2016, 172, 105-110. | 1.4 | 43 |
| 106 | Clinical Profiling of BCL-2 Family Members in the Setting of BRAF Inhibition Offers a Rationale for Targeting De Novo Resistance Using BH3 Mimetics. PLoS ONE, 2014, 9, e101286. | 1.1 | 42 |
| 107 | FOXD3 Regulates VISTA Expression in Melanoma. Cell Reports, 2020, 30, 510-524.e6. | 2.9 | 42 |
| 108 | Dual roles of lineage restricted transcription factors. Transcription, 2011, 2, 19-22. | 1.7 | 41 |

| # | ARTICLE | IF | CITATIONS |
|---|---|---|---|
| 109 | Melanocyte stem cells as potential therapeutics in skin disorders. Expert Opinion on Biological Therapy, 2014, 14, 1569-1579. | 1.4 | 41 |
| 110 | The melanomaâ€•linked â€œredheadâ€•<i>MC1R</i> influences dopaminergic neuron survival. Annals of Neurology, 2017, 81, 395-406. | 2.8 | 41 |
| 111 | Biology of Melanoma. Hematology/Oncology Clinics of North America, 2021, 35, 29-56. | 0.9 | 40 |
| 112 | Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination Treatment. PLoS ONE, 2015, 10, e0140310. | 1.1 | 39 |
| 113 | ROCK inhibitor enhances the growth and migration of BRAFâ€•mutant skin melanoma cells. Cancer Science, 2018, 109, 3428-3437. | 1.7 | 36 |
| 114 | Topical treatment strategies to manipulate human skin pigmentation. Advanced Drug Delivery Reviews, 2020, 153, 65-71. | 6.6 | 35 |
| 115 | NNT mediates redox-dependent pigmentation via a UVB- and MITF-independent mechanism. Cell, 2021, 184, 4268-4283.e20. | 13.5 | 35 |
| 116 | New Strategies in Metastatic Melanoma: Oncogene-Defined Taxonomy Leads to Therapeutic Advances. Clinical Cancer Research, 2011, 17, 4922-4928. | 3.2 | 34 |
| 117 | Biologic Activity of Autologous, Granulocyteâ€"Macrophage Colony-Stimulating Factor Secreting Alveolar Soft-Part Sarcoma and Clear Cell Sarcoma Vaccines. Clinical Cancer Research, 2015, 21, 3178-3186. | 3.2 | 34 |
| 118 | Understanding the Biology of Melanoma and Therapeutic Implications. Hematology/Oncology Clinics of North America, 2014, 28, 437-453. | 0.9 | 33 |
| 119 | Transcription Factor Tfe3 Directly Regulates Pgcâ€•1alpha in Muscle. Journal of Cellular Physiology, 2015, 230, 2330-2336. | 2.0 | 33 |
| 120 | In vivo coherent Raman imaging of the melanomagenesis-associated pigment pheomelanin. Scientific Reports, 2016, 6, 37986. | 1.6 | 33 |
| 121 | Topical ROR Inverse Agonists Suppress Inflammation in Mouse Models of Atopic Dermatitis and Acute Irritant Dermatitis. Journal of Investigative Dermatology, 2017, 137, 2523-2531. | 0.3 | 32 |
| 122 | SOX10 Regulates Melanoma Immunogenicity through an IRF4â€"IRF1 Axis. Cancer Research, 2021, 81, 6131-6141. | 0.4 | 31 |
| 123 | Signaling and Immune Regulation in Melanoma Development and Responses to Therapy. Annual Review of Pathology: Mechanisms of Disease, 2017, 12, 75-102. | 9.6 | 30 |
| 124 | Central role for cAMP signaling in pigmentation and UV resistance. Cell Cycle, 2011, 10, 8-9. | 1.3 | 29 |
| 125 | MSX1-Induced Neural Crest-Like Reprogramming Promotes MelanomaÂProgression. Journal of Investigative Dermatology, 2018, 138, 141-149. | 0.3 | 29 |
| 126 | Chemoprevention agents for melanoma: A path forward into phase 3 clinical trials. Cancer, 2019, 125, 18-44. | 2.0 | 29 |

| # | ARTICLE | IF | CITATIONS |
|---|---|---|---|
| 127 | Hdac3 is an epigenetic inhibitor of the cytotoxicity program in CD8 T cells. Journal of Experimental Medicine, 2020, 217, . | 4.2 | 28 |
| 128 | Microphthalmia: A Signal Responsive Transcriptional Regulator in Development. Pigment Cell & Melanoma Research, 2000, 13, 145-149. | 4.0 | 25 |
| 129 | Notch and Melanocytes: Diverse Outcomes from a Single Signal. Journal of Investigative Dermatology, 2008, 128, 2571-2574. | 0.3 | 25 |
| 130 | Red Hair, Light Skin, and UV-Independent Risk for Melanoma Development in Humans. JAMA Dermatology, 2016, 152, 751. | 2.0 | 24 |
| 131 | Specification and loss of melanocyte stem cells. Seminars in Cell and Developmental Biology, 2009, 20, 111-116. | 2.3 | 23 |
| 132 | Transcriptional Regulation in Melanoma. Hematology/Oncology Clinics of North America, 2009, 23, 447-465. | 0.9 | 21 |
| 133 | Disproportionate Burden of Melanoma Mortality in Young US Men. JAMA Dermatology, 2013, 149, 903. | 2.0 | 21 |
| 134 | Immunotherapy in the Precision Medicine Era: Melanoma and Beyond. PLoS Medicine, 2016, 13, e1002196. | 3.9 | 21 |
| 135 | Neural crest state activation in NRAS driven melanoma, but not in NRAS-driven melanocyte expansion. Developmental Biology, 2019, 449, 107-114. | 0.9 | 19 |
| 136 | Chest wall recurrence of ductal carcinoma in situ of the breast after mastectomy. Cancer, 1993, 71, 3025-3028. | 2.0 | 18 |
| 137 | Myosin-Va Contributes to Manifestation of Malignant-Related Properties in Melanoma Cells. Journal of Investigative Dermatology, 2013, 133, 2809-2812. | 0.3 | 17 |
| 138 | A Novel Role for Microphthalmia-Associated Transcription Factorâ€"Regulated Pigment Epithelium-Derived Factor during Melanoma Progression. American Journal of Pathology, 2015, 185, 252-265. | 1.9 | 17 |
| 139 | Tfe3 and Tfeb Transcriptionally Regulate Peroxisome Proliferator-Activated Receptor Î³2 Expression in Adipocytes and Mediate Adiponectin and Glucose Levels in Mice. Molecular and Cellular Biology, 2017, 37, . | 1.1 | 17 |
| 140 | The lncRNA RMEL3 protects immortalized cells from serum withdrawalâ€induced growth arrest and promotes melanoma cell proliferation and tumor growth. Pigment Cell and Melanoma Research, 2019, 32, 303-314. | 1.5 | 17 |
| 141 | Lineage-specific control of TFIIH by MITF determines transcriptional homeostasis and DNA repair. Oncogene, 2019, 38, 3616-3635. | 2.6 | 17 |
| 142 | Non-Euclidean phasor analysis for quantification of oxidative stress in ex vivo human skin exposed to sun filters using fluorescence lifetime imaging microscopy. Journal of Biomedical Optics, 2017, 22, 1. | 1.4 | 17 |
| 143 | Vitamin D deficiency exacerbates UV/endorphin and opioid addiction. Science Advances, 2021, 7, . | 4.7 | 16 |
| 144 | FHL2 switches MITF from activator to repressor of Erbin expression during cardiac hypertrophy. International Journal of Cardiology, 2015, 195, 85-94. | 0.8 | 15 |

| # | Article | IF | Citations |
|---|---|---|---|
| 145 | Inhibition of Cell Proliferation in an NRAS Mutant Melanoma Cell Line by Combining Sorafenib and Î±-Mangostin. PLoS ONE, 2016, 11, e0155217. | 1.1 | 14 |
| 146 | Developing melanoma therapeutics: overview and update. Wiley Interdisciplinary Reviews: Systems Biology and Medicine, 2013, 5, 257-271. | 6.6 | 13 |
| 147 | Highâ€throughput, highâ€content screening for novel pigmentation regulators using a keratinocyte/melanocyte coâ€culture system. Experimental Dermatology, 2014, 23, 125-129. | 1.4 | 13 |
| 148 | Local genomic features predict the distinct and overlapping binding patterns of the bHLHâ€Zip family oncoproteins MITF and MYCâ€MAX. Pigment Cell and Melanoma Research, 2019, 32, 500-509. | 1.5 | 13 |
| 149 | Topical therapy for regression and melanoma prevention of congenital giant nevi. Cell, 2022, 185, 2071-2085.e12. | 13.5 | 13 |
| 150 | Stressâ€associated ectopic differentiation of melanocyte stem cells and ORS amelanotic melanocytes in an ex vivo human hair follicle model. Experimental Dermatology, 2021, 30, 578-587. | 1.4 | 12 |
| 151 | The Impact of MITF on Melanoma Development: News from Bench and Bedside. Journal of Investigative Dermatology, 2014, 134, 16-17. | 0.3 | 11 |
| 152 | CYP27A1-dependent anti-melanoma activity of limonoid natural products targets mitochondrial metabolism. Cell Chemical Biology, 2021, 28, 1407-1419.e6. | 2.5 | 11 |
| 153 | Monitoring Repair of UV-Induced 6-4-Photoproducts with a Purified DDB2 Protein Complex. PLoS ONE, 2014, 9, e85896. | 1.1 | 11 |
| 154 | Targeting melanoma by small molecules: challenges ahead. Pigment Cell and Melanoma Research, 2013, 26, 464-469. | 1.5 | 10 |
| 155 | Rational Combination Therapy for Melanoma with Dinaciclib by Targeting BAK-Dependent Cell Death. Molecular Cancer Therapeutics, 2020, 19, 627-636. | 1.9 | 10 |
| 156 | MYO5A Gene Is a Target of MITF inÂMelanocytes. Journal of Investigative Dermatology, 2017, 137, 985-989. | 0.3 | 9 |
| 157 | Hair repigmentation associated with the use of brentuximab. JAAD Case Reports, 2017, 3, 563-565. | 0.4 | 9 |
| 158 | Feasibility of Ultra-High-Throughput Functional Screening of Melanoma Biopsies for Discovery of Novel Cancer Drug Combinations. Clinical Cancer Research, 2017, 23, 4680-4692. | 3.2 | 8 |
| 159 | G9a: An Emerging Epigenetic Target for Melanoma Therapy. Epigenomes, 2021, 5, 23. | 0.8 | 8 |
| 160 | Melanocortin 1 receptor activation protects against alpha-synuclein pathologies in models of Parkinsonâ€™s disease. Molecular Neurodegeneration, 2022, 17, 16. | 4.4 | 8 |
| 161 | Nonmalignant late cutaneous changes after allogeneic hematopoietic stem cell transplant in children. Journal of the American Academy of Dermatology, 2018, 79, 230-237. | 0.6 | 7 |
| 162 | A ROCK inhibitor promotes keratinocyte survival and paracrine secretion, enhancing establishment of primary human melanocytes and melanocyteâ€“keratinocyte coâ€cultures. Pigment Cell and Melanoma Research, 2020, 33, 16-29. | 1.5 | 7 |

| # | Article | IF | Citations |
|---|---|---|---|
| 163 | Perioperative Serum 25-Hydroxyvitamin D Levels as a Predictor of Postoperative Opioid Use and Opioid Use Disorder: a Cohort Study. Journal of General Internal Medicine, 2020, 35, 2545-2552. | 1.3 | 7 |
| 164 | Reduced MC4R signaling alters nociceptive thresholds associated with red hair. Science Advances, 2021, 7, . | 4.7 | 7 |
| 165 | Turning p53 on or off: either way may treat cancer. Drug Resistance Updates, 2000, 3, 77-79. | 6.5 | 6 |
| 166 | UV and melanoma: the TP53 link. Cell Research, 2014, 24, 1157-1158. | 5.7 | 6 |
| 167 | Bioinformatic Analysis of Gene Expression for Melanoma Treatment. Journal of Investigative Dermatology, 2016, 136, 2342-2344. | 0.3 | 6 |
| 168 | Melanocortin 1 receptor is dispensable for acute stress induced hair graying in mice. Experimental Dermatology, 2021, 30, 572-577. | 1.4 | 6 |
| 169 | Targeting the (Un)differentiated State of Cancer. Cancer Cell, 2018, 33, 793-795. | 7.7 | 5 |
| 170 | Tanning as a substance abuse. Communicative and Integrative Biology, 2014, 7, e971579. | 0.6 | 4 |
| 171 | Pathways in melanoma development. Italian Journal of Dermatology and Venereology, 2018, 153, 68-76. | 0.1 | 4 |
| 172 | Biology of Melanocytes and Primary Melanoma. , 2020, , 3-40. |  | 4 |
| 173 | Metabolic Vulnerability in Melanoma: A ME2 (Me Too) Story. Journal of Investigative Dermatology, 2015, 135, 657-659. | 0.3 | 3 |
| 174 | Microphthalmiaâ€associated transcription factor phosphorylation: Cross talk between GSK3 and MAPK signaling. Pigment Cell and Melanoma Research, 2019, 32, 345-347. | 1.5 | 3 |
| 175 | Epitope Spreading and the Efficacy of Immune Checkpoint Inhibition in Cancer. International Journal of Oncology Research, 2021, 4, . | 0.1 | 2 |
| 176 | Extensive apoptosis in ductal carcinoma in situ of the breast. , 1996, 77, 1831. |  | 2 |
| 177 | Dual Targeting with EZH2 Inhibitor and STING Agonist to Treat Melanoma. Journal of Investigative Dermatology, 2022, 142, 1004-1006. | 0.3 | 2 |
| 178 | Authors' Reply. American Journal of Pathology, 2015, 185, 2070. | 1.9 | 1 |
| 179 | Negative Regulation of Skin Pigmentation in Three-Dimensional Reconstructs by Adipose-Derived Mesenchymal Cells. Journal of Investigative Dermatology, 2017, 137, 2464-2466. | 0.3 | 1 |
| 180 | miRNA-211 stops the clock. Non-coding RNA Investigation, 2018, 2, 25-25. | 0.6 | 1 |

| # | Article | IF | Citations |
|---|---|---|---|
| 181 | Hormones and Hormone Precursors of the Skin. , 2020, , 531-556. | | 1 |
| 182 | The Melanocyte Lineage Factor miR-211 Promotes BRAFV600E Inhibitor Resistance. Journal of Investigative Dermatology, 2021, 141, 250-252. | 0.3 | 1 |
| 183 | Transcriptional Regulation in Melanoma. , 2011, , 79-103. | | 1 |
| 184 | Blood mRNA signature to predict survival in patients with metastatic melanoma treated with tremelimumab.. Journal of Clinical Oncology, 2013, 31, 9080-9080. | 0.8 | 1 |
| 185 | The Biology of Pigmentation. , 2018, , 1-30. | | 1 |
| 186 | Scientific and social controversies regarding UV and pigmentation: the beneficial effects of UV irradiance outweighs the risks - a reply. Pigment Cell and Melanoma Research, 2009, 22, 139-139. | 1.5 | 0 |
| 187 | Preface. Hematology/Oncology Clinics of North America, 2009, 23, xiii-xiv. | 0.9 | 0 |
| 188 | Shin-Ichi Nishikawa MD, PhD. Pigment Cell and Melanoma Research, 2010, 23, 683-683. | 1.5 | 0 |
| 189 | GENE-18. DIVERGENT CLONAL EVOLUTION OF MELANOMA BRAIN METASTASES DURING TREATMENT WITH IMMUNOTHERAPY. Neuro-Oncology, 2018, 20, vi106-vi107. | 0.6 | 0 |
| 190 | The Biology of Pigmentation. , 2019, , 21-50. | | 0 |
| 191 | Sun exposure and protection practices in children after allogeneic hematopoietic stem cell transplantation: A Surveyâ€Based Crossâ€Sectional Cohort Study. Pediatric Dermatology, 2019, 36, 882-886. | 0.5 | 0 |
| 192 | MFN2 Stabilization: A Bridge for Endoplasmic Reticulum Stress Sensitivity in Melanoma. Journal of Investigative Dermatology, 2021, 141, 2782-2784. | 0.3 | 0 |
| 193 | Transcriptional Regulation in Melanoma. , 2017, , 95-117. | | 0 |
| 194 | Biology of Melanocytes and Primary Melanoma. , 2019, , 1-38. | | 0 |
| 195 | Commentary on NNT Mediates Redox-Dependent Pigmentation a UVB-And MITF-Independent Mechanism.. Journal of Cell Science & Therapy, 2021, 12, . | 0.3 | 0 |